Dr. Maranchie is a surgical oncologist specializing in urologic cancers of the urinary tract and male genitalia.  She completed urology residency at Harvard University in 1999, followed by a fellowship in Urologic Oncology at the National Cancer Institute.  Her practice is focused on the care of patients with cancer of the kidney, bladder and testis, employing minimally invasive approaches, nephron-sparing and nerve-sparing surgery and urinary tract reconstruction.  She has specialty expertise in familial or inherited cancer syndromes, offering targeted surveillance with organ-preserving surgery when indicated. LGBTQIA+ Affirming: This provider has completed training on how to create a safe, comfortable, and welcoming environment for LGBTQIA+ patients. This provider may or may not offer LGBTQIA+ specific medical or surgical care. Please ask when scheduling. Dr. Maranchie is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Nephrectomy, and Cystectomy.

Stephen Jackman, MD, is a urologic surgeon focused on minimally invasive surgery for kidney and prostate cancer as well as kidney stones. His areas of specialty include surgical techniques involving advanced laparoscopy, robotics, and complex kidney stone disease. Dr. Jackman is Professor and Vice Chair of Urology at the University of Pittsburgh School of Medicine. Dr. Jackman is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Kidney Stones, Boils, Folliculitis, Ureteroscopy, and Endoscopy.

Gregory Halenda, MD, is certified in urology by the American Board of Urology. He is affiliated with UPMC Magee-Womens Hospital.  Dr. Halenda received his medical degree from Thomas Jefferson University Medical College and completed his residency at Penn State University College of Medicine. Dr. Halenda is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Enlarged Prostate (BPH), Kidney Stones, Perirenal Abscess, Prostatectomy, and Ureteroscopy.

Dr. Michael C. Ost is a urologist who treats a wide array of urologic conditions in both adults and children. He is skilled in minimally invasive surgery, utilizing robotics, laparoscopy, and endourologic techniques. His areas of expertise include the treatment of kidney cancer, congenital renal anomalies, ureteral injuries and abnormalities, and complex stone disease. Dr. Ost received his medical degree from the Mount Sinai School of Medicine in New York City. He received subspecialty fellowship training in both endourology (Northwell Health System – New York) and pediatric urology (UPMC Children’s Hospital of Pittsburgh). He was the first urologist in the United States to receive such training to treat a wide spectrum of urologic diseases in a minimally invasive fashion in both adults and children. He is widely published and has lectured nationally and internationally on his areas of specialization. Dr. Ost also received his MBA from the Ross School of Business at the University of Michigan. In addition to his clinical practice as a professor of urology, Dr. Ost serves as Director of Pediatric Surgical Outreach at UPMC Children’s Hospital of Pittsburgh and Assistant Dean for Interprofessional Education and Technology at the University of Pittsburgh School of Medicine. Dr. Ost is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Anorchia, Ureterocele, UPJ Obstruction, Lithotripsy, and Ureteroscopy.

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

David Friedland is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Friedland is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Quoc-Dien Trinh, MD, MBA, serves as the Chair of the Department of Urology, University of Pittsburgh School of Medicine, and Chair of Urology, UPMC. A globally recognized urological surgeon-scientist, Dr. Trinh has been honored with the 2021 Outstanding Citizenship Award from Brigham and Women’s Hospital and the 2022 American Urological Association Young Urologist of the Year award for New England. He is recognized as a Castle Connolly Top Doctor and a Top Asian American Pacific Islander Doctor. Dr. Trinh is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Bladder Cancer, Urothelial Cancer, Prostatectomy, and Cystectomy.

Joel D. Bigley, MD, is an assistant professor of urology at the University of Pittsburgh School of Medicine. He received his medical degree from the West Virginia School of Medicine in Morgantown, W. Va., and also completed residencies in general surgery and urology at the University of Pittsburgh. Dr. Bigley is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Kidney Stones, Boils, Folliculitis, Ureteroscopy, and Lithotripsy.

Tatum V. Tarin, MD, is an Associate Professor of Urology at the University of Pittsburgh School of Medicine. He earned his medical degree from the University of Pittsburgh, and completed residencies in surgery and urology at Stanford University Medical Center. He also completed a fellowship in urological oncology at Memorial Sloan-Kettering Cancer Center in New York, N.Y., where he was a clinical instructor for two years prior to joining UPMC. Dr. Tarin is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Lymphadenectomy, and Nephrectomy.

Bishoy A. Gayed, MD, is an assistant professor of urology at the University of Pittsburgh School of Medicine. He received his medical degree from the University of Missouri Kansas City. Dr. Gayed completed his residency in urology at UPMC and a fellowship in urologic oncology at the University of Texas Southwestern Medical Center. He specializes in urology, urologic oncology, urologic surgery, and the management of tumors of the kidney, bladder, prostate, ureteral, testicular, penile, and adrenal cancers. Dr. Gayed is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Hydronephrosis, Nephrectomy, and Ureteroscopy.

Ronald L. Hrebinko, MD, is a professor of urology at the University of Pittsburgh School of Medicine. He specializes in all genitourinary cancers with special expertise in continent urinary diversion, nephron-sparing surgery for renal cancer, laparoscopic kidney surgery, nerve-sparing surgery for the prostate, and testis cancer. Dr. Hrebinko is board-certified in urology. He received an undergraduate degree with honors from Dartmouth College in N.H., and a medical degree at the University of Pittsburgh School of Medicine. Dr. Hrebinko completed a residency at UPMC in the Department of Surgery, and a fellowship at Roswell Park Cancer Institute, in Buffalo, N.Y. Dr. Hrebinko is a member of professional organizations, such as the American Urologic Association, Society of Urologic Oncology, and the American Society of Clinical Oncology. Are you already a patient of this provider and have a MyUPMC account? Log in to MyUPMC to schedule. Dr. Hrebinko is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, Nephrectomy, and Reconstructive Urology Surgery.

Roby A. Thomas, MD, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. Dr. Thomas is trained in the management of all cancers and blood disorders with a focus in genitourinary and gastrointestinal malignancies. Dr. Thomas is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Gamma Knife Radiosurgery, and Endoscopy.

Vikram C. Gorantla, MD, specializes in the treatment of sarcoma, breast cancer, gastrointestinal malignancies, and head and neck cancers. Board-certified in internal medicine and medical oncology, he received his medical degree at the University of Texas Southwestern Medical School in Dallas. He completed his internal medicine residency at Washington University, St. Louis, MO, and his hematology/oncology fellowship at UPMC. Dr. Gorantla has a dedicated day seeing breast cancer patients at the Magee-Womens Cancer Progam. He also collaborates with surgical oncologists and gynecologists/oncologists to provide multidisciplinary care to patients. Dr. Gorantla is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, Gamma Knife Radiosurgery, and Endoscopy.

Ronald Brennan, MD, specializes in diagnostic radiology and is certified in diagnostic radiology by the American Board of Radiology. He practices at University of Pittsburgh Physicians, Department of Radiology and is affiliated with UPMC Horizon, and UPMC Jameson. He completed his medical degree at Hahnemann University Hospital and residency at Mount Sinai Medical Center. Dr. Brennan is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Ascites, Cerebellar Multiple System Atrophy, Hepatocerebral Degeneration, and Cerebellar Degeneration.

Jason Luke is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Luke is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

Benjamin J. Davies, MD, is a professor of urology at the University of Pittsburgh. He specializes in robotic prostatectomy, robotic cystectomy, and kidney and testicular cancer. Dr. Davies is board-certified in urology. He completed an undergraduate degree at Columbia University in New York and a medical degree at Mount Sinai Medical School in New York. Dr. Davies completed a residency at UPMC, and a fellowship of urologic oncology at University of California, San Francisco. Dr. Davies is a member of professional organizations, such as the American Urologic Association, American Medical Association and the Pittsburgh Urologic Society. He also maintains research interests in prostate cancer epidemiology and surgical outcomes. Dr. Davies is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Urothelial Cancer, Vasectomy, and Reconstructive Urology Surgery.

Daniel P. Petro, MD, is a medical oncologist and hematologist at Hillman Cancer Center. He treats all cancer types, and has a special interest in a multidisciplinary approach to thoracic malignancies. Dr. Petro is also heavily involved in the research of Phase I trials. Dr. Petro is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Gamma Knife Radiosurgery, and Awake Craniotomy.

Anwaar Saeed, MD, is an Associate Professor of Medicine and the Chief of the Gastrointestinal (GI) Medical Oncology Program at the University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), and UPMC Hillman Cancer Center. She also serves as the Vice Chair of the Colorectal Cancer Committee of the NSABP Foundation. Her research efforts are focused on immune modulatory approaches in patients with gastric & esophageal cancer, colon cancer and hepatocellular carcinoma as well as chemoprevention/ immunoprevention in the high-risk GI population. She has published more than 150 peer reviewed papers, posters and book chapters, and have led more than 40 clinical trials, focused on various immune modulatory regimens including but not limited to immune checkpoint inhibitor combinations with chemotherapy, other checkpoint inhibitors, antibody drug conjugates, bi-specific T cell engagers (BiTE), angiogenesis inhibitors, as well as immunotherapy combinations with regional approaches like stereotactic radiosurgery and intensity-modulated radiation therapy. She currently leads several investigator-initiated trials focused on novel targeted immunotherapy combinations including the ongoing phase I/II CAMILLA multicohort study looking at Cabozantinib plus Durvalumab with or without Tremelimumab in GI malignancies. Results from phase I/II part of the CAMILLA led to the development of the currently ongoing global pivotal trial, STELLAR 303, in patients with previously treated microsatellite stable colorectal cancer. She is also the study chair for a soon to open SWOG/intergroup NCI national trial (S2303) testing a novel chemo-immunotherapy regimen in patients with advanced gastric & esophageal adenocarcinoma. Dr. Saeed is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Stomach Cancer, Cataract Removal, and Gamma Knife Radiosurgery.

Zahra Rahman Kelly, DO, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. Dr. Kelly is trained in the management of all cancers and blood disorders with a focus in genitourinary and head and neck malignancies.  Dr. Kelly is board-certified in nternal medicine and medical oncology and hematology. She received her medical degree from Philadelphia College of Osteopathic Medicine. Dr. Kelly completed both a residency in internal medicine and a fellowship in hematology/oncology at UPMC. She served as chief fellow during her final year of hematology/oncology fellowship. Her research interests include early phase clinical trial design and cancer immunotherapy combination trials. She has published papers in peer reviewed journals and is an active member of the UPMC Hillman protocol review committee where she reviews therapeutic oncology trials. She also collaborates with surgical oncologists and radiation oncologists to provide multidisciplinary care to her patients. Dr. Kelly is a member of the European Society of Medical Oncology, American Society of Medical Oncology, American Medical Association, and American Society of Hematology. Dr. Kelly is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Febrile Neutropenia, Chronic Familial Neutropenia, and Gamma Knife Radiosurgery.

Bruce L. Jacobs, MD, is an associate professor of urology at the University of Pittsburgh School of Medicine. He received a medical degree from the Vanderbilt University School of Medicine in Nashville, Tenn., and earned a master’s degree in public health from the University of Michigan School of Public Health. Dr. Jacobs completed residencies in general surgery and urology at the University of Pittsburgh, and fellowships in health services research, laparoscopy/endourology, and urologic oncology at the University of Michigan. Dr. Jacobs is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Prostatectomy.